Plant Name: Orostachys fimbriata
Taxonomic Information:
Plant ID: NPO26823
Plant Latin Name: Orostachys fimbriata
Taxonomy Genus: Orostachys
Taxonomy Family: Crassulaceae
Plant External Links:
NCBI TaxonomyDB:
91113
Plant-of-the-World-Online:
274617-1
Used in Medicines:
Unknown.
Geographical Distribution:
China; Mongolia; South Africa
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ALPL; TDP1; HSD17B10; PGD; HSD17B2; | |
| BCL2; | |
| FYN; | |
| CA2; CA7; CA4; CA6; CA12; | |
| TYR; | |
| KDM4E; | |
| AHR; NFKB1; | |
| FUT7; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Protein Kinase | FYN | Tyrosine-protein kinase FYN | P06241 | CHEMBL1841 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.710E-12 | 5.900E-08 | CA12, CA2, CA4, CA6, CA7 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.353E-10 | 3.650E-06 | CA12, CA2, CA4, CA6, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 9.605E-10 | 6.972E-06 | CA12, CA2, CA4, CA6, CA7 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.322E-07 | 3.160E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0009636; response to toxic substance | 1.451E-07 | 3.160E-04 | AHR, ALPL, BCL2, CYP1A1, CYP1B1, FYN, NFKB1 |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 4.841E-07 | 8.817E-04 | ALPL, BCL2, CA2, CYP1A1, CYP1A2, HSD17B2, NFKB1, TYR |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 5.102E-07 | 8.817E-04 | ALPL, BCL2, CA2, CYP1A1, CYP1A2, CYP1B1, NFKB1, TYR |
| MF | GO:0005488; binding | GO:0046914; transition metal ion binding | 7.681E-07 | 1.195E-03 | CA12, CA2, CA4, CA6, CA7, CYP1A1, CYP1A2, CYP1B1, TYR |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.454E-06 | 1.979E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.934E-06 | 2.217E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.934E-06 | 2.217E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 2.506E-06 | 2.480E-03 | CYP1A1, CYP1A2, CYP1B1, HSD17B10, HSD17B2, KDM4E, PGD, TYR |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.375E-06 | 2.812E-03 | CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 6.746E-06 | 4.896E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0032451; demethylase activity | 9.869E-06 | 6.932E-03 | CYP1A1, CYP1A2, KDM4E |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 4.687E-12 | 4.546E-10 | CA12, CA2, CA4, CA7, CA6 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 3.673E-07 | 1.781E-05 | CYP1A2, HSD17B2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 9.614E-06 | 3.108E-04 | CYP1A2, CYP1A1, CYP1B1 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 2.086E-05 | 4.046E-04 | FUT7, HSD17B2, CYP1A2, CYP1A1, ALPL, PGD, TYR, HSD17B10 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.894E-05 | 4.046E-04 | HSD17B2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.919E-05 | 9.568E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 8.376E-05 | 1.161E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 4.071E-04 | 3.949E-03 | LMNA, BCL2, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 2.589E-04 | 2.825E-03 | BCL2, FYN, NFKB1 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 2.622E-04 | 2.825E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; CA2; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | BCL2; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | BCL2; |
| C00-D49: Neoplasms | Colon cancer | C50 | ALPL; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| NA: NA | HIV infections | NA | AHR; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | TYR; |
| G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2; |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| C00-D49: Neoplasms | Melanoma | C43 | TYR; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
| C00-D49: Neoplasms | Breast cancer | C50 | BCL2; |
| C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| C00-D49: Neoplasms | Cancer | C00-C96 | NFKB1; BCL2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | BCL2; |
| C00-D49: Neoplasms | Prostate cancer | C61 | BCL2; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | BCL2; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; BCL2; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
